Clinical Oncology/Epidemiology in 1993

A model of long-term survival following adjuvant therapy for stage 2 breast cancer

• JW Gamel
• RL Vogel

A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer

• TJ Hamblin
• S Sadullah
• CR Franks

Micronutrients in gastrointestinal cancer

• SN Georgiannos
• PMT Weston
• AW Goode

Hospice management of patients receiving cytotoxic chemotherapy: problems and opportunities

• F Hicks
• G Corcoran

Early stage cervical cancer: psychosocial and sexual outcomes of treatment

• A Cull
• VJ Cowie
• RA Elton

Cancer in the population of Hanoi, Vietnam, 1988-1990

• Pham Thi Hoang Anh
• DM Parkin
• Nguyen Ba Duc

Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease

• R García
• JM Hernández
• JF San Miguel

Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical

• T Tatsumura
• S Koyama
• S Kagamimori

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma

• TJ Perren
• E Wiltshaw
• PR Blake

Testicular function following the treatment of Hodgkin's disease in childhood

• EA Shafford
• JE Kingston
• OB Eden

Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer

• CJ Williams
• VL Barley
• CJ Tyrrell

Are plant factors a missing link in the evolution of endemic Burkitt's lymphoma?

• C van den Bosch
• BE Griffin
• L Kadzamira

Expression of MDR1/P glycoprotein in human sarcomas

• B Vergier
• L Cany
• JM Coindre

Multiple primary tumours in a population-based series of patients with histopathologically peer-reviewed sarcomas

• AL Hartley
• V Blair
• LJ McWilliam

Trends in breast cancer incidence in Sweden 1958-1988 by time period and birth cohort

• I Persson
• R Bergström
• H-O Adami

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life

• NM Bleehen
• DJ Girling
• RJ Stephens

Interim analyses and stopping rules in cancer clinical trials

• J Whitehead

A simulated sequential analysis based on data from two MRC trials

• AN Donaldson
• J Whitehead
• D Machin

A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors

• NM Bleehen
• DJ Girling
• RJ Stephens

Trends in lip cancer incidence in Vaud, Switzerland

• F Levi
• C La Vecchia
• S Franceschi